Combination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity LA JOLLA, Calif. / Oct 07, 2024 / Business Wire / Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for poster presentation at the 39 th Annual Meeting of... Read More